Comparing the current results to its competitors, Curis Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.17 %, recorded in the same quarter.
Curis Inc , slower than the average decrease reported by the company's competitors of -32.24 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -32.24 %
Curis Inc 's Comment on Competition and Industry Peers
Emavusertib, if approved, will compete with existing and emerging therapies targeting similar cancer indications. The market for human therapeutics focused on signaling pathways in cancer treatment is highly competitive and rapidly evolving, involving large pharmaceutical, biopharmaceutical, and specialized biotechnology companies with greater resources. Key competitors developing treatments for oncology indications such as IRAK4, chronic lymphocytic leukemia (CLL), primary central nervous system lymphoma (PCNSL), acute myeloid leukemia (AML) with FLT3 mutation, and frontline AML combinations with azacitidine and venetoclax include Kurome Therapeutics (KME-0584), Rigel Pharmaceuticals, Inc. (R289), AstraZeneca (AZD2962), Hangzhou Polymed Biopharmaceuticals (HPB-092), and Eilean Therapeutics (lomonitinib). AstraZeneca also markets an approved BTK inhibitor, acalabrutinib. Additional competitors include Shattuck Labs, Inc. (SL-17254), Bio-Path Holdings, Inc. (prexigebersen), Astellas Pharma, Inc. (gilteritinib), and AbbVie Inc. (pivekimab sunirine). Many of these companies possess substantially greater research, development, manufacturing, marketing, financial capabilities, and experience in clinical trials and regulatory approvals, which may provide competitive advantages.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Clene Inc's business model focuses on developing and commercializing novel nanocatalysts to enhance energy storage systems and improve the efficiency and performance of clean energy technologies.
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
Perspective Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapeutic solutions. Their business model involves conducting extensive research and development to create novel drug candidates targeting specific diseases. They aim to collaborate with pharmaceutical companies and seek partnerships to further develop and commercialize their products, ultimately making a positive impact on patients' lives.
Carisma Therapeutics Inc's business model focuses on developing novel CAR-Macrophage cell therapies to treat solid tumors. They aim to leverage their proprietary technology platform to engineer immune cells that can effectively target and destroy cancer cells, while also optimizing the manufacturing process for scalability and cost-effectiveness.
Sources:
Curis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Curis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
